<p class="MsoNormal"><span style="color:#000000">US pharmaceutical major Pfizer Wednesday revised its revenue forecast from the sale of its COVID-19 vaccine in 2021 by 29% to $33.5 billion. Earlier, the company had pegged its full-year sales forecast from its COVID-19 vaccine at $26 billion. </span></p>
